Medicinal Chemistry & Pharmacology
BioIVT Strengthens Biorepository and Advances Research with PrecisionMed Acquisition
The acquisition of PrecisionMed by BioIVT marks a momentous occasion in the biospecimen industry.
Neuropharmacological Potential of Rho-Kinase Inhibition in Schizophrenia-Associated Mutations
Researchers investigated the therapeutic effects of ROCK inhibition in a mouse model with ARHGAP10 gene mutations, offering insights into the genetic basis of schizophrenia.
Bionanofluidics and the Future of Drug Delivery
Lately, nanofluids have expanded their range of biological research applications, particularly as novel means of medication delivery.
Data-Driven Deal: Biosero and Virscidian Double Down on Drug Discovery
Biosero and Virscidian’s latest deal advances medicinal chemistry with the help of their combined analytics technologies.
Pillaranenes: Juicing Up Poison Management with Capture Chemistry
Shown to function as an in vivo sequestration agent for methamphetamine and fentanyl, Pillar[6]MaxQ (P6AS) has significant potential for development as a broad-spectrum in vivo sequestrant.
Latest Organochem Acquisition Expands GD3’s Preclinical Chemistry Services Market
Genesis Drug Discovery & Development broadens its chemistry services market scope with its latest acquisition of Organochem.
Harnessing Liposomal Amphiphilicity for Novel Drug Delivery
Formerly bangosomes, liposomal structures now pave the way for improved drug delivery with increased bioavailability and reduced toxicity.
Molecular Modeling Advancements Seen in CD ComputaBio’s Latest Software Suites
Latest molecular docking software suites shown to advance computational biology efforts of CD ComputaBio.
Revisiting Macrocycles in Drug Discovery
Macrocyclic drugs offer a bridge between traditional small molecules and biologic drugs. We explore current work on them.
Aptamers: Successes and Challenges Ahead
Aptamers promise the possibility of chemical antibodies and more – but more work is needed to advance this fledgling modality
April 2022 Drug Launch Highlights
Highlights from drugs approved by the FDA in April 2022 – novel treatments for rare diseases, heart disorders and vaginal yeast infection.
March 2022 Drug Launch Highlights
March saw new drug approvals by the FDA – including multiple agents in oncology, novel Alzheimer’s treatments, and the first LAG-3 inhibitor
Rediscovering Covalent Drugs
Covalent drugs were largely abandoned with the advent of target-based drug discovery. Their resurgence in the last decade has come on the coat-tails of technological progress and brings promising developments for unment needs.
Chemoproteomics in Phenotypic Drug Discovery
Chemoproteomics is a natural complement of phenotypic drug discovery. We examine developments in the area and its future potentials.
PROTACs Enter the Clinic: A Brief History
PROTACs have been a promising new treatment modality for years – we examine their recent history and innovations that show their potential
The Rise of Multispecific Drugs
Multispecific drugs promise to be one of the big waves of innovation in pharma – we examine the main modalities and their impact.